ASSESSMENT OF THE INFLUENCE OF ANTICOAGULANT THERAPY ON COVID-19 COURSE AND OUTCOME

The advent of COVID-19 has given the tasks to healthcare professionals of quickly diagnosing and providing medical care to patients. Currently, an intensive study of the clinical and epidemiological characteristics of the disease is being carried out, and the new ways of its prevention and treatment are being developed. The most common clinical manifestation of a new variant of coronavirus infection is bilateral pneumonia (viral diffuse alveolar damage with microangiopathy); the development of acute respiratory distress syndrome (ARDS) was recorded in 3-4% of patients. Hypercoagulable syndrome with thrombosis and thromboembolism are developing in some organs of patients, other organs and systems are also affected (central nervous system, myocardium, kidneys, liver, gastrointestinal tract, endocrine and immune systems); the development of sepsis and septic shock is possible [1]. The use of anticoagulant therapy with low molecular weight heparins (LMWH) reduces mortality in hospitalized patients with severe form of COVID-19, likely due to its anti-inflammatory and antiviral properties [5]. There is no proven benefit of one LMWH over another. In the suspicion of the development of venous thromboembolic complications, anticoagulant therapy can be started in therapeutic doses before the diagnosis is confirmed: during the period of inpatient treatment, LMWH should be preferred, especially Enoxaparin sodium (Clexane) or UFH, and after discharge from the hospital, it is recommended to switch to direct parenteral anticoagulants, in particular Rivaroksaban NOBEL for a period of at least 3 months [1]. The purpose of this work is to carry out a comparative assessment of the effect of anticoagulants on the clinical and laboratory course and the outcome of coronavirus infection (COVID-19).

Keywords:

anticoagulant therapy, COVID-19, diffuse alveolar damage, respiratory distress syndrome, venous thromboembolism

1. Временные методические рекомендации по профилактике, диагностике, лечению и реабилитации при коронавирусной инфекции (COVID-19), Версия 8, 2020. (03.09.2020). 2. Громов А.А.,КручининаМ.В., Рабко А.В. Коронавирусная болезнь COVID-19: неиспользованные возможности терапии. РМЖ. 2020, №9. С.2-6. 3. Cuker A., Tseng EK., Nieuwlaat R. et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv (2021) 5 (3): 872–888. 4. Di Micco P, Russo V, Carannante N, Imparato M, Rodolfi S, Cardillo G, et al. Clotting factors in COVID-19: epidemiological association andprognostic values in different clinical presentations in an Italian Cohort.J Clin Med. (2020) 9:1371. 5. Fontana P, Casini A, Robert-Ebadi H, Glauser F, Righini M, Blondon M. Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines. Swiss Med Wkly. (2020) 150:w20301. 6. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. (2020) 8:e46–7. 7. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. ESC Scientific Document Group developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. (2020) 41:543–603. 8. M. Levi, M. Scully, How I treat disseminated intravascular coagulation. Blood. (2018) 131:845–54. 9. McCloskey B, Heymann DL. SARS to novel coronavirus: old lessons and new lessons. EpidemiolInfect. (2020) 148:e22. 10. Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. (2020) 158:1143–63. 11. Russo V, Bottino R, Carbone A, Rago A, Papa AA, Golino P, et al. COVID-19 and heart: from clinical features to pharmacological implications.J Clin Med. (2020) 9:E1944. 12. Russo V, Rago A, Carbone A, Bottino R, Ammendola E, Della Cioppa N, et al. Atrial fibrillation in COVID-19: from epidemiological association to pharmacological implications. J Cardiovasc Pharmacol. (2020) 76:138–45. 13. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. (2020) 18:1094– 9. 14. Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366(01):9–19. 15. EikelboomJW, Connolly SJ, Bosch J, et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377(14):1319–1330. 16. Cohen AT, Spiro TE, Büller HR, et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013;368(06):513–523. 17. Spyropoulos AC, Ageno W, Albers GW, et al; MARINER Investigators. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med 2018;379(12):1118–1127. 18. Cohen AT, Harrington RA, Goldhaber SZ, et al; APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 2016;375(06):534–544.